Tango Therapeutics, Inc. (TNGX)
$22.22-8.07%Close
SELLRECOVERY · day 3
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $2.8B
- Beta
- 1.17
- P/E (TTM)
- -26.14
- Short % float
- 54.26%
- Days to cover
- 12.5
- SI change
- +6.3%
- 1W
- +1.46%
- 1M
- -9.45%
- vs SPY 1W
- +1.60%
- vs SPY 1M
- -11.96%
Industry peers
FMP comparable companies · ranked by market cap
- RVMDSELLRevolution Medicines, Inc.$40.3BRECOVERYQ 30$189.76-2.84%
- ERASSELLErasca, Inc.$5.6BRECOVERYQ 4$16.03-4.40%
- RLAYSELLRelay Therapeutics, Inc.$3.9BRECOVERYQ 2$17.88-3.45%
- IDYASELLIDEAYA Biosciences, Inc.$3.4BBEARQ 25$36.11-4.99%
- NRIXSELLNurix Therapeutics, Inc.$2.3BBEARQ 11$22.35-0.14%
- NUVBSELLNuvation Bio Inc.$1.7BCRISISQ 4$5.00-3.67%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on TNGX?
- LOPJLB’s latest quantitative signal on Tango Therapeutics, Inc. (TNGX) is SELL in a RECOVERY regime. Signals are updated daily.
- What market regime is TNGX in?
- Tango Therapeutics, Inc. (TNGX) is currently classified in the RECOVERY HMM market regime on LOPJLB.
- What does Tango Therapeutics, Inc. (TNGX) do?
- Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphoryla…